GERALD T PROEHL
CIK 1279191 · President, CEO and Chairman · last filed 2026-01-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$464.1K
Companies
7
Total Filings
56
Lifetime Open-Market Net
-$10.78M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TENX | Director | 1,667 | $15.80 | $26.3K | $50.0K | 8 | 2026-01-13 |
| DRMAW | President, CEO and Chairman | 31 | $0.01 | $0 | $97.6K | 8 | 2026-01-06 |
| THC | Director | 1,667 | $262.63 | $437.8K | $0 | 1 | 2024-08-08 |
| SOPHIRIS BIO INC. (SPHS) Delisted | Director | 10,000 | — | — | $31.6K | 7 | 2019-06-28 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 2,000 | — | — | $250.0K | 4 | 2018-01-25 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Director | 0 | — | — | $31.9K | 2 | 2015-05-06 |
| SANTARUS INC (SNTS) Delisted | President & CEO | 416,463 | — | — | -$11.24M | 25 | 2013-12-17 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-05 | DRMAW | Grant (A) | — | $0 | EDGAR |
| 2021-11-26 | DRMAW | Buy (P) | +20,000 | $48.0K | EDGAR |
| 2021-08-17 | DRMAW | Mixed | +2,203,636 | $49.6K | EDGAR |
| 2021-06-15 | TENX | Grant (A) | — | $0 | EDGAR |
| 2020-05-15 | TENX | Grant (A) | — | $0 | EDGAR |
| 2019-06-28 | SOPHIRIS BIO INC. (SPHS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-18 | TENX | Grant (A) | — | $0 | EDGAR |
| 2018-06-28 | SOPHIRIS BIO INC. (SPHS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-25 | Qualigen Therapeutics, Inc. (RTTR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-01 | SOPHIRIS BIO INC. (SPHS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.